JP2000044481A - Preparation for external use for skin - Google Patents
Preparation for external use for skinInfo
- Publication number
- JP2000044481A JP2000044481A JP10230069A JP23006998A JP2000044481A JP 2000044481 A JP2000044481 A JP 2000044481A JP 10230069 A JP10230069 A JP 10230069A JP 23006998 A JP23006998 A JP 23006998A JP 2000044481 A JP2000044481 A JP 2000044481A
- Authority
- JP
- Japan
- Prior art keywords
- extract
- skin
- plant
- preparation
- external use
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 239000000284 extract Substances 0.000 claims abstract description 58
- 235000006484 Paeonia officinalis Nutrition 0.000 claims abstract description 8
- 235000001637 Ganoderma lucidum Nutrition 0.000 claims abstract description 7
- 240000008397 Ganoderma lucidum Species 0.000 claims abstract description 7
- 241000220317 Rosa Species 0.000 claims abstract description 7
- 241001116389 Aloe Species 0.000 claims abstract description 6
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 6
- 235000007232 Matricaria chamomilla Nutrition 0.000 claims abstract description 6
- 235000008708 Morus alba Nutrition 0.000 claims abstract description 6
- 240000000249 Morus alba Species 0.000 claims abstract description 6
- 241000736199 Paeonia Species 0.000 claims abstract description 6
- 235000009827 Prunus armeniaca Nutrition 0.000 claims abstract description 6
- 244000018633 Prunus armeniaca Species 0.000 claims abstract description 6
- 235000006040 Prunus persica var persica Nutrition 0.000 claims abstract description 6
- 244000178231 Rosmarinus officinalis Species 0.000 claims abstract description 6
- 241000543810 Sasa veitchii Species 0.000 claims abstract description 6
- 235000011399 aloe vera Nutrition 0.000 claims abstract description 6
- 244000000626 Daucus carota Species 0.000 claims abstract description 5
- 235000002767 Daucus carota Nutrition 0.000 claims abstract description 5
- 244000144730 Amygdalus persica Species 0.000 claims abstract description 4
- 235000007354 Coix lacryma jobi Nutrition 0.000 claims abstract description 3
- 244000077995 Coix lacryma jobi Species 0.000 claims abstract description 3
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 3
- 235000009814 Luffa aegyptiaca Nutrition 0.000 claims abstract description 3
- 244000042664 Matricaria chamomilla Species 0.000 claims abstract 2
- 235000010181 horse chestnut Nutrition 0.000 claims abstract 2
- 241001474374 Blennius Species 0.000 claims description 6
- 235000007866 Chamaemelum nobile Nutrition 0.000 claims description 5
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims description 5
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims description 5
- 229940010454 licorice Drugs 0.000 claims description 5
- 241000208690 Hamamelis Species 0.000 claims description 4
- 240000000073 Achillea millefolium Species 0.000 claims description 3
- 235000007754 Achillea millefolium Nutrition 0.000 claims description 3
- 235000012432 gingerbread Nutrition 0.000 claims description 3
- 244000280244 Luffa acutangula Species 0.000 claims description 2
- 235000014443 Pyrus communis Nutrition 0.000 claims 2
- 241000157282 Aesculus Species 0.000 claims 1
- 235000017060 Arachis glabrata Nutrition 0.000 claims 1
- 244000105624 Arachis hypogaea Species 0.000 claims 1
- 235000010777 Arachis hypogaea Nutrition 0.000 claims 1
- 235000018262 Arachis monticola Nutrition 0.000 claims 1
- 244000111489 Gardenia augusta Species 0.000 claims 1
- 235000020232 peanut Nutrition 0.000 claims 1
- 208000003251 Pruritus Diseases 0.000 abstract description 13
- 241000196324 Embryophyta Species 0.000 abstract description 9
- 206010061218 Inflammation Diseases 0.000 abstract description 8
- 230000004054 inflammatory process Effects 0.000 abstract description 6
- 240000001972 Gardenia jasminoides Species 0.000 abstract description 5
- 241000220225 Malus Species 0.000 abstract description 5
- 239000000419 plant extract Substances 0.000 abstract description 5
- 244000124853 Perilla frutescens Species 0.000 abstract description 4
- 230000002401 inhibitory effect Effects 0.000 abstract description 4
- 235000006886 Zingiber officinale Nutrition 0.000 abstract description 3
- 244000273928 Zingiber officinale Species 0.000 abstract description 3
- 235000008397 ginger Nutrition 0.000 abstract description 3
- 241000722941 Achillea Species 0.000 abstract 1
- 241000157280 Aesculus hippocastanum Species 0.000 abstract 1
- 241000544270 Angelica acutiloba Species 0.000 abstract 1
- 235000017519 Artemisia princeps Nutrition 0.000 abstract 1
- 244000065027 Artemisia princeps Species 0.000 abstract 1
- 235000003932 Betula Nutrition 0.000 abstract 1
- 241000219429 Betula Species 0.000 abstract 1
- 240000001432 Calendula officinalis Species 0.000 abstract 1
- 235000005881 Calendula officinalis Nutrition 0.000 abstract 1
- 241000195493 Cryptophyta Species 0.000 abstract 1
- 241000195950 Equisetum arvense Species 0.000 abstract 1
- 239000005768 Equisetum arvense L. Substances 0.000 abstract 1
- 235000018958 Gardenia augusta Nutrition 0.000 abstract 1
- 241000208680 Hamamelis mollis Species 0.000 abstract 1
- 240000008669 Hedera helix Species 0.000 abstract 1
- 241000110847 Kochia Species 0.000 abstract 1
- 244000045575 Luffa cylindrica Species 0.000 abstract 1
- 244000246386 Mentha pulegium Species 0.000 abstract 1
- 235000016257 Mentha pulegium Nutrition 0.000 abstract 1
- 235000004357 Mentha x piperita Nutrition 0.000 abstract 1
- 235000008598 Paeonia lactiflora Nutrition 0.000 abstract 1
- 244000236658 Paeonia lactiflora Species 0.000 abstract 1
- 235000004348 Perilla frutescens Nutrition 0.000 abstract 1
- 235000008282 Sanguisorba officinalis Nutrition 0.000 abstract 1
- 244000173853 Sanguisorba officinalis Species 0.000 abstract 1
- 235000017089 Scutellaria baicalensis Nutrition 0.000 abstract 1
- 240000004534 Scutellaria baicalensis Species 0.000 abstract 1
- 241000246044 Sophora flavescens Species 0.000 abstract 1
- 235000001050 hortel pimenta Nutrition 0.000 abstract 1
- 239000001841 zingiber officinale Substances 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 14
- 230000000694 effects Effects 0.000 description 13
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- 210000003491 skin Anatomy 0.000 description 12
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 11
- 239000004615 ingredient Substances 0.000 description 10
- 239000002674 ointment Substances 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 239000003205 fragrance Substances 0.000 description 8
- 235000011187 glycerol Nutrition 0.000 description 7
- -1 if necessary Substances 0.000 description 7
- LXCFILQKKLGQFO-UHFFFAOYSA-N p-hydroxybenzoic acid methyl ester Natural products COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 7
- 240000006891 Artemisia vulgaris Species 0.000 description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- 230000003110 anti-inflammatory effect Effects 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 229960001340 histamine Drugs 0.000 description 6
- 229960003511 macrogol Drugs 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000008213 purified water Substances 0.000 description 6
- 235000003826 Artemisia Nutrition 0.000 description 5
- 206010030113 Oedema Diseases 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 244000030166 artemisia Species 0.000 description 5
- 235000009052 artemisia Nutrition 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 239000006210 lotion Substances 0.000 description 5
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 description 4
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
- 235000007173 Abies balsamea Nutrition 0.000 description 4
- 239000004857 Balsam Substances 0.000 description 4
- 235000018185 Betula X alpestris Nutrition 0.000 description 4
- 235000018212 Betula X uliginosa Nutrition 0.000 description 4
- 240000003538 Chamaemelum nobile Species 0.000 description 4
- 244000018716 Impatiens biflora Species 0.000 description 4
- 235000006679 Mentha X verticillata Nutrition 0.000 description 4
- 235000002899 Mentha suaveolens Nutrition 0.000 description 4
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 4
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 4
- 239000004359 castor oil Substances 0.000 description 4
- 235000019438 castor oil Nutrition 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000013329 compounding Methods 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 235000013399 edible fruits Nutrition 0.000 description 4
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 4
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 4
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 4
- 229960002216 methylparaben Drugs 0.000 description 4
- 229940105902 mint extract Drugs 0.000 description 4
- 239000001509 sodium citrate Substances 0.000 description 4
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 4
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 241000195955 Equisetum hyemale Species 0.000 description 3
- 240000004670 Glycyrrhiza echinata Species 0.000 description 3
- 240000005979 Hordeum vulgare Species 0.000 description 3
- 235000007340 Hordeum vulgare Nutrition 0.000 description 3
- 235000003956 Luffa Nutrition 0.000 description 3
- 244000050983 Luffa operculata Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 235000004347 Perilla Nutrition 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 210000002683 foot Anatomy 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000007803 itching Effects 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 3
- 208000017520 skin disease Diseases 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 2
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 2
- 235000003840 Amygdalus nana Nutrition 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 206010012438 Dermatitis atopic Diseases 0.000 description 2
- 235000009811 Momordica charantia Nutrition 0.000 description 2
- 235000009812 Momordica cochinchinensis Nutrition 0.000 description 2
- 240000001740 Momordica dioica Species 0.000 description 2
- 235000018365 Momordica dioica Nutrition 0.000 description 2
- 244000170916 Paeonia officinalis Species 0.000 description 2
- 235000011432 Prunus Nutrition 0.000 description 2
- 241000220299 Prunus Species 0.000 description 2
- 240000005809 Prunus persica Species 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 241000555745 Sciuridae Species 0.000 description 2
- 206010039986 Senile pruritus Diseases 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 229960002684 aminocaproic acid Drugs 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- CUFNKYGDVFVPHO-UHFFFAOYSA-N azulene Chemical compound C1=CC=CC2=CC=CC2=C1 CUFNKYGDVFVPHO-UHFFFAOYSA-N 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 229940075507 glyceryl monostearate Drugs 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 210000003630 histaminocyte Anatomy 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 239000010330 ougon Substances 0.000 description 2
- 235000014774 prunus Nutrition 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 229940032094 squalane Drugs 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- YJLIKUSWRSEPSM-WGQQHEPDSA-N (2r,3r,4s,5r)-2-[6-amino-8-[(4-phenylphenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1CNC1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O YJLIKUSWRSEPSM-WGQQHEPDSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- CIVCELMLGDGMKZ-UHFFFAOYSA-N 2,4-dichloro-6-methylpyridine-3-carboxylic acid Chemical compound CC1=CC(Cl)=C(C(O)=O)C(Cl)=N1 CIVCELMLGDGMKZ-UHFFFAOYSA-N 0.000 description 1
- JRLTTZUODKEYDH-UHFFFAOYSA-N 8-methylquinoline Chemical group C1=CN=C2C(C)=CC=CC2=C1 JRLTTZUODKEYDH-UHFFFAOYSA-N 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- 235000005940 Centaurea cyanus Nutrition 0.000 description 1
- 240000004385 Centaurea cyanus Species 0.000 description 1
- 241000219122 Cucurbita Species 0.000 description 1
- 235000009854 Cucurbita moschata Nutrition 0.000 description 1
- 240000004244 Cucurbita moschata Species 0.000 description 1
- 235000009852 Cucurbita pepo Nutrition 0.000 description 1
- 241000208296 Datura Species 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 101000879758 Homo sapiens Sjoegren syndrome nuclear autoantigen 1 Proteins 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- 244000081841 Malus domestica Species 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- 240000004371 Panax ginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 241000109329 Rosa xanthina Species 0.000 description 1
- 235000004789 Rosa xanthina Nutrition 0.000 description 1
- 102100037330 Sjoegren syndrome nuclear autoantigen 1 Human genes 0.000 description 1
- 241001441724 Tetraodontidae Species 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 229940069521 aloe extract Drugs 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000021016 apples Nutrition 0.000 description 1
- 229940069780 barley extract Drugs 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 229940105847 calamine Drugs 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229920002055 compound 48/80 Polymers 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 238000004332 deodorization Methods 0.000 description 1
- 229960000525 diphenhydramine hydrochloride Drugs 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000002795 fluorescence method Methods 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 235000020710 ginseng extract Nutrition 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 229910052864 hemimorphite Inorganic materials 0.000 description 1
- 210000000548 hind-foot Anatomy 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- DXGLGDHPHMLXJC-UHFFFAOYSA-N oxybenzone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1 DXGLGDHPHMLXJC-UHFFFAOYSA-N 0.000 description 1
- 229960001173 oxybenzone Drugs 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000003504 photosensitizing agent Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 238000006748 scratching Methods 0.000 description 1
- 230000002393 scratching effect Effects 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 1
- 229960000401 tranexamic acid Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 235000014692 zinc oxide Nutrition 0.000 description 1
- CPYIZQLXMGRKSW-UHFFFAOYSA-N zinc;iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+3].[Fe+3].[Zn+2] CPYIZQLXMGRKSW-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
【0001】[0001]
【発明の属する技術分野】本発明は、特定植物の抽出エ
キスを組み合わせて配合することにより、優れた炎症抑
制作用、ならびにかゆみ抑制作用を有する、皮膚外用剤
に関する。TECHNICAL FIELD The present invention relates to an external preparation for skin having an excellent inflammation-suppressing action and an itching-inhibiting action when combined with extracts of specific plants.
【0002】[0002]
【従来技術と課題】近年、アトピー性皮膚炎や老人性掻
痒症などの皮膚疾患が問題とされており、その患者は年
々増えている。これら皮膚疾患は、かゆみを伴う疾患と
して知られているが、かゆみが患者に精神的に苦痛を与
えるとともに、掻く事により症状を悪化させてしまう。
これらの皮膚疾患の予防または治療すべく、各種の外用
剤が提案されている。例えば、副腎皮質ホルモンは優れ
た抗炎症剤であり、疾患に対して優れた炎症抑制効果、
かゆみ抑制効果を有するものの、副作用面での懸念があ
り、満足のできる治療薬とは言い難い。また、皮膚に対
する作用が緩和なものとして、植物エキスを用いること
も考えられており、かゆみ・炎症を抑制するものとして
提案されている。2. Description of the Related Art In recent years, skin diseases such as atopic dermatitis and senile pruritus have been regarded as problems, and the number of patients has been increasing year by year. These skin diseases are known as itch-related diseases, but itching causes mental discomfort to the patient and worsens the symptoms by scratching.
In order to prevent or treat these skin diseases, various external preparations have been proposed. For example, corticosteroids are excellent anti-inflammatory agents and have excellent anti-inflammatory effects on diseases,
Although it has an itching-suppressing effect, there are concerns about side effects, and it is hard to say that it is a satisfactory therapeutic agent. It is also considered to use a plant extract as a substance having a mild effect on the skin, and it has been proposed to suppress itching and inflammation.
【0003】[0003]
【課題を解決するための手段】本発明者らは、かゆみと
炎症の抑制に有効な、天然由来の薬剤を鋭意検討した。
すなわち、かゆみの誘発物質としては、ヒスタミンがよ
く知られており、ヒスタミンが肥満細胞の脱顆粒により
組織内に遊離し、かゆみを起こし、これが炎症の起こる
初期反応であることから、本発明者らは、種々の植物エ
キスについてヒスタミン遊離抑制作用(in vitr
o)および起炎剤(compound48/80)に対
する抗炎症作用(in vivo)を指標にして探索し
たところ、特定の植物の抽出エキスを併用することによ
り、より優れた炎症抑制作用およびかゆみ抑制作用を発
揮する事を見出し、本発明を完成させるに至った。Means for Solving the Problems The present inventors diligently studied a naturally occurring drug which is effective in suppressing itch and inflammation.
That is, histamine is well known as an itch-inducing substance, and histamine is released into tissues by degranulation of mast cells, causing itch, which is an initial reaction in which inflammation occurs. Has a histamine release inhibitory effect (in vitro) on various plant extracts.
o) and an anti-inflammatory effect (in vivo) against an inflammatory agent (compound 48/80) were searched for as an index. By using an extract of a specific plant in combination, a more excellent anti-inflammatory and anti-itch effect was obtained. They have found out that they have achieved this, and have completed the present invention.
【0004】[0004]
【発明の実施の形態】すなわち、本発明は、クララ、ホ
ウセンカ、ミントから選ばれる少なくとも1種以上の抽
出エキスと、ヨモギ、当帰、ワレモコウ、カンゾウ、アロ
エ、ヘチマ、オウゴン、海藻、カミツレ、クチナシ、ク
マザサ、クワ、シソ、シラカバ、スギナ、セイヨウノコ
ギリソウ、ニンジン、ハマメリス、バラ、マロニエ、マ
ンネンタケ、トウキセンカ、ローズマリー、リンゴ、セ
イヨウキズク、ハトムギ、モモ、アンズ、シャクヤク、
ショウキョウ、ホウキギ、ボタンピから選ばれる少なく
とも1種以上の抽出エキスとを併用することを特徴とす
る優れた炎症抑制作用およびかゆみ抑制作用を発揮す
る、皮膚外用剤に関する。DESCRIPTION OF THE PREFERRED EMBODIMENTS That is, the present invention relates to an extract of at least one selected from Clara, Balsam, and mint, as well as mugwort, toki, waremokou, licorice, aloe, luffa, giant gourd, seaweed, chamomile and gardenia. , Kumazasa, Mulberry, Perilla, Birch, Horsetail, Caribbean, Hawberry, Rose, Marronnier, Mannentake, Toukisenka, Rosemary, Apple, Atlantic Owl, Barley, Peach, Apricot, Peony,
The present invention relates to an external preparation for skin, which exhibits an excellent inflammation-suppressing action and itching-suppressing action, characterized in that it is used in combination with at least one or more extracted extracts selected from ginger, pufferfish and buttonpicks.
【0005】本発明に用いられる植物は、全草もしくは
好ましい部位を用いることができる。たとえば、クララ
は根を、ホウセンカは花を、ミントは葉を、ヨモギは葉
を、当帰は根を、ワレモコウは根を、カンゾウは根を、
アロエは葉を、ヘチマは地上部を、オウゴンは根を、カ
ミツレは花を、クチナシは果実を、クマザサは葉を、ク
ワは根を、シソは葉を、シラカバは樹皮を、ニンジンは
根を、ハマメリスは葉、根、樹皮を、バラは花を、マン
ネンタケは子実体を、トウキンセンカは花を、ローズマ
リーは葉または花を、リンゴは果実を、ハトムギは種子
を、モモは種子または果実または葉を、アンズは種子
を、シャクヤクは根を、ショウキョウは根を用いるのが
好ましい。 これらの植物からの抽出エキスは以下の方法で得る事が
できる。 例えば、植物の生または乾燥物を、水または水性有機溶
媒で抽出する。抽出溶媒は通常、原料の2〜5倍容量加
え、2〜3回繰り返し抽出するのが好ましい。抽出は水で
十分に行えるが、抽出液の腐敗防止や、抽出を促進するた
めに水性有機溶媒を用いてもよい。水性有機溶媒として
は、例えば、メタノールやエタノールのような低級アルコ
ールが挙げられる。 また、この抽出は加温によって促進され、原料は破砕もし
くは粉砕するのが好ましい。 尚、これらの成分は、そのままの形で化粧料に配合する
事に何ら問題はないが、必要に応じて脱色や脱臭等の目
的のために活性炭等の処理をおこなってもかまわない。[0005] The plant used in the present invention may be whole plant or a preferable part. For example, Clara has roots, Balsam has flowers, mint has leaves, mugworts have leaves, Toki has roots, Warm Mocks has roots, Licorice has roots,
Aloe for leaves, loofah for above-ground parts, ogre for roots, chamomile for flowers, gardenia for fruits, Kumazasa for leaves, mulberry for roots, perilla for leaves, birch for bark, carrots for roots. , Hamamelis leaves, roots, bark, roses, flowers, ginseng, fruit bodies, rosemary, flowers, rosemary, leaves or flowers, apples, fruits, adlay seeds, peaches, seeds or fruits. Or leaves, apricots use seeds, peonies use roots, and ginger use roots. Extracts extracted from these plants can be obtained by the following method. For example, a raw or dried plant is extracted with water or an aqueous organic solvent. Usually, it is preferable that the extraction solvent is added 2 to 5 times the volume of the raw material and the extraction is repeated 2 to 3 times. Although extraction can be sufficiently performed with water, an aqueous organic solvent may be used to prevent decay of the extract and to promote extraction. Examples of the aqueous organic solvent include lower alcohols such as methanol and ethanol. This extraction is promoted by heating, and the raw material is preferably crushed or pulverized. It should be noted that there is no problem if these components are incorporated into the cosmetics as they are, but they may be treated with activated carbon or the like for the purpose of decolorization or deodorization as required.
【0006】このようにして得られた特定植物エキスを
併用した皮膚外用剤は、後述のように優れた抗炎症、抗か
ゆみ作用を有し、さらに肌荒れ防止・改善効果にも優れ
た効果を発揮する事が判明した。これらの効果は0.0
01〜20%重量の範囲で配合した時、好ましくは両エ
キスをそれぞれ0.1〜10%重量配合した時に顕著に
認められる。[0006] The external preparation for skin combined with the specific plant extract thus obtained has an excellent anti-inflammatory and anti-itch effect as described later, and also has an excellent effect of preventing and improving rough skin. It turned out to be. These effects are 0.0
It is remarkably observed when it is blended in the range of 01 to 20% by weight, and preferably when both extracts are blended in the amount of 0.1 to 10% by weight.
【0007】本発明の皮膚外用剤には、植物抽出エキス
に加え、必要に応じ、本発明の効果をそこなわない範囲で
化粧品、医薬部外品、医薬品等に一般に用いられる抗炎症
作用を有する成分、例えば、オキシベンゾン、トラネキサ
ム酸、およびその誘導体、アラントイン、イプシロンアミ
ノカプロン酸、グリチルリチン酸、感光素301号、40
1号、塩酸ジフェンヒドラミン、アデノシン酸、カラミ
ン、水溶性アズレン、アミノカプロン酸、サリチル酸、ビサ
ポロールエキス等の1種または2種以上を配合してもよ
い。[0007] The external preparation for skin of the present invention has an anti-inflammatory effect commonly used in cosmetics, quasi-drugs, pharmaceuticals, etc., in addition to the plant extract, if necessary, as long as the effects of the present invention are not impaired. Ingredients, for example, oxybenzone, tranexamic acid, and derivatives thereof, allantoin, epsilon aminocaproic acid, glycyrrhizic acid, Photosensitizer No. 301, 40
No. 1, one or two or more of diphenhydramine hydrochloride, adenosine acid, calamine, water-soluble azulene, aminocaproic acid, salicylic acid, and bisapolol extract may be blended.
【0008】さらに本発明の外用剤には、前期の有効成
分に加え、必要に応じ、本発明の効果をそこなわない範囲
で化粧品、医薬部外品、医薬品等に一般に用いられる成
分、例えば界面活性剤、グリセリン、1、3-ブチレングリコ
ール、ヒアルロン酸、セラミド等の保湿剤、紫外線吸収剤
や紫外線散乱剤、また増粘剤、防腐剤、酸化防止剤、香料、
色剤等を配合する事ができる。また本発明の外用剤の剤
系は任意であり、例えば、水溶液系、可溶化系、乳化系、粉
末系、油液系、ゲル系、軟膏系等の剤系で調製する事がで
きる。The external preparation of the present invention may further contain, in addition to the above-mentioned active ingredients, if necessary, components generally used in cosmetics, quasi-drugs, pharmaceuticals, etc. as long as the effects of the present invention are not impaired. Activators, humectants such as glycerin, 1,3-butylene glycol, hyaluronic acid, ceramide, ultraviolet absorbers and ultraviolet scattering agents, thickeners, preservatives, antioxidants, fragrances,
A coloring agent or the like can be blended. The agent system of the external preparation of the present invention is arbitrary, and for example, it can be prepared in an agent system such as an aqueous solution system, a solubilizing system, an emulsifying system, a powder system, an oil liquid system, a gel system and an ointment system.
【0009】[0009]
【実施例】以下、実験例をあげて、発明の効果を説明す
る。実験例1 <抽出エキスの調製>植物の乾燥物400gを50%(V
/V)エタノール水溶液5リットルに浸漬した後、2時間
加熱還流にて抽出を行った。その後同量のエタノール:
水混液を用いて同様に2時間加熱還流にて抽出を行った
後に、抽出液を濾過して合し、その後減圧下で溶媒留去
により乾固することで、褐色粉末状物質を得た。EXAMPLES The effects of the present invention will be described below with reference to experimental examples. EXPERIMENTAL EXAMPLE 1 <Preparation of Extract> 400 g of dried plant material was added to 50% (V
/ V) After immersion in 5 liters of an aqueous ethanol solution, extraction was performed by heating under reflux for 2 hours. Then the same amount of ethanol:
After similarly extracting with heating and refluxing for 2 hours using a water mixture, the extracts were combined by filtration, and then evaporated to dryness under reduced pressure to obtain a brown powdery substance.
【0010】<ヒスタミン遊離抑制試験>雄性ラット(W
ister/ST系、体重約150g)を用い、腹腔内に0.1%
BSAリン酸緩衝液を注入し、常法に従って肥満細胞を
分取し、細胞浮遊液を調製した。この浮遊液2mlに前
記抽出エキスを25μg/ml(最終濃度)もしくは50μg/m
l(最終濃度)、もしくは5μg/ml〜25μg/ml(最終濃
度)の範囲で前記抽出エキスを組み合わせて添加した。
前記抽出エキス添加10分後に起炎剤(compoun
d48/80)を添加し、10分間の遊離および細胞内
ヒスタミン量を蛍光法で定量し、数1で示される式に従
って遊離抑制率(%)を算出した。結果を表1に示す。<Histamine release inhibition test> Male rats (W
ister / ST system, weight about 150g), 0.1% intraperitoneally
BSA phosphate buffer was injected, mast cells were collected according to a conventional method, and a cell suspension was prepared. 25 μg / ml (final concentration) or 50 μg / m
l (final concentration), or a combination of the above extracts in the range of 5 μg / ml to 25 μg / ml (final concentration).
10 minutes after the addition of the extracted extract,
d48 / 80) was added, and the amount of free and intracellular histamine for 10 minutes was quantified by a fluorescence method, and the release inhibition rate (%) was calculated according to the formula shown in Equation 1. Table 1 shows the results.
【0011】[0011]
【数1】 (Equation 1)
【0012】[0012]
【表1】 [Table 1]
【0013】表1に示すように、ホウセンカ、ミント、
クララから選ばれる少なくとも1種以上の抽出エキス
と、ヨモギ、当帰、ワレモコウ、カンゾウ、アロエ、ヘチ
マ、オウゴン、海藻、カミツレ、クチナシ、クマザサ、
クワ、シソ、シラカバ、スギナ、セイヨウノコギリソ
ウ、ニンジン、ハマメリス、バラ、マロニエ、マンネン
タケ、トウキセンカ、ローズマリー、リンゴ、セイヨウ
キズク、ハトムギ、モモ、アンズ、シャクヤク、ショウ
キョウ、ホウキギ、ボタンピから選ばれる少なくとも1
種以上の抽出エキスとを併用した場合、抽出エキスを単
独で、同量用いた場合に比べても、相乗的に、ヒスタミ
ン遊離を抑制することがわかる。[0013] As shown in Table 1, balsam, mint,
At least one or more extracted extracts selected from Clara, mugwort, toki, waremokou, licorice, aloe, luffa, ougon, seaweed, chamomile, gardenia, kumazasa,
At least one selected from mulberry, perilla, birch, horsetail, Achillea millefolium, carrot, hamamelis, rose, marronnier, mannenthus mushroom, cornflower, rosemary, apple, prunus omelette, barley, peach, apricot, peonies, gingerbread, squirrel, buttonpipi
It can be seen that when more than one kind of extract is used in combination, histamine release is synergistically suppressed as compared with the case where the same amount of extract is used alone.
【0014】<足浮腫抑制試験>2.5重量%もしくは
5.0重量%の前記抽出エキス、もしくは各々を2.5
重量%ずつ混合したエキスを、マクロゴール軟膏に配合
し、これを雄性ラット(Wister/ST系、体重約150g)の
右後足に塗布し、4時間後、同右後足せき皮下に、起炎
剤として生理食塩水に溶解したcompound48/
80を皮下注射した。その30分後に足容積測定装置に
よって腫れ容積を測定し、数2で示される式に従って浮
腫率を算出し、またエキスを配合しないマクロゴール軟
膏を塗布した対照群での浮腫率との比較により数3で示
される式に従って抑制率を算出した。結果を表2に示
す。<Paw edema inhibition test> 2.5% by weight or 5.0% by weight of the above-mentioned extract or 2.5% by weight of each extract
The extract mixed by weight% was mixed into macrogol ointment, which was applied to the right hind paw of a male rat (Wister / ST system, body weight: about 150 g). Compound48 / dissolved in physiological saline
80 was injected subcutaneously. Thirty minutes later, the swelling volume was measured by a foot volume measuring device, the edema rate was calculated according to the equation shown in Equation 2, and the edema rate was compared with the edema rate in a control group to which Macrogol ointment containing no extract was applied. The suppression rate was calculated according to the formula shown in FIG. Table 2 shows the results.
【0015】[0015]
【数2】 (Equation 2)
【0016】[0016]
【数3】 (Equation 3)
【0017】[0017]
【表2】 [Table 2]
【0018】表2に示すように、ホウセンカ、ミント、
クララから選ばれる少なくとも1種以上の抽出エキス
と、ヨモギ、当帰、ワレモコウ、カンゾウ、アロエ、ヘチ
マ、オウゴン、海藻、カミツレ、クチナシ、クマザサ、
クワ、シソ、シラカバ、スギナ、セイヨウノコギリソ
ウ、ニンジン、ハマメリス、バラ、マロニエ、マンネン
タケ、トウキセンカ、ローズマリー、リンゴ、セイヨウ
キズク、ハトムギ、モモ、アンズ、シャクヤク、ショウ
キョウ、ホウキギ、ボタンピから選ばれる少なくとも1
種以上の抽出エキスとを併用した場合、抽出エキスを単
独で、同量用いた場合に比べても、相乗的に、足浮腫を
抑制することがわかる。さらに、実施例1の軟膏を肌荒
れを起こしている人の皮膚に塗布した場合、肌荒れ改善
効果があることも確認された。As shown in Table 2, the balsam, mint,
At least one or more extracted extracts selected from Clara, mugwort, toki, waremokou, licorice, aloe, luffa, ougon, seaweed, chamomile, gardenia, kumazasa,
At least one selected from mulberry, perilla, birch, horsetail, Achillea millefolium, carrot, hamamelis, rose, marronnier, mannentake, toukisenka, rosemary, apple, prunus sylvestris, barley, peach, apricot, peonies, gingerbread, squirrel, buttonpipi
It can be seen that when more than one kind of extract is used in combination, paw edema is synergistically suppressed as compared with the case where the same amount of extract is used alone. Furthermore, it was also confirmed that when the ointment of Example 1 was applied to the skin of a person having rough skin, there was an effect of improving the rough skin.
【0019】実施例27:軟膏 成分 配合量(重量%) ヨモギエキス 2.5 クララエキス 2.5 プロピレングリコール#400 15.0 マクロゴール軟膏 80.0 実験例1で得たヨモギエキスおよびクララエキスをプロ
ピレングリコール#400に均一に分散させた後、マクロゴ
ール軟膏を加えて混合する。Example 27: Ointment Ingredients Compounding amount (% by weight) Artemisia extract 2.5 Clara extract 2.5 Propylene glycol # 400 15.0 Macrogol ointment 80.0 The artemisia extract and Clara extract obtained in Experimental example 1 are uniformly dispersed in propylene glycol # 400. After that, macrogol ointment is added and mixed.
【0020】 実施例28:軟膏 成分 配合量(重量%) バラエキス 1.5 ヨモギエキス 1.0 ホウセンカエキス 2.5 プロピレングリコール#400 15.0 マクロゴール軟膏 80.0 実験例1で得たバラエキスおよびヨモギエキスおよびホ
ウセンカエキスをプロピレングリコール#400に均一に分
散させた後、マクロゴール軟膏を加えて混合する。Example 28: Ointment Ingredients Compounding amount (% by weight) Rose extract 1.5 Artemisia extract 1.0 Balsam extract 2.5 Propylene glycol # 400 15.0 Macrogol ointment 80.0 The rose extract, artemisia extract and artemisia extract obtained in Experimental Example 1 were converted to propylene glycol # 400. And then add Macrogol ointment and mix.
【0021】 実施例29:化粧水 成分 配合量(重量%) ヨモギエキス 1.0 海藻エキス 1.0 マンネンタケエキス 1.0 ミントエキス 1.0 クララエキス 1.0 グリセリン 6.0 エタノール 9.0 ポリオキシエチレン硬化ヒマシ油 0.8 メチルパラベン 0.05 クエン酸 0.05 クエン酸ナトリウム 0.07 香料 0.1 精製水 残部 合計 100.0 精製水にグリセリン、クエン酸、クエン酸ナトリウム、
実験例1で得たヨモギエキスおよび海藻エキスおよびマ
ンネンタケエキスおよびミントエキスおよびクララエキ
スを溶解する。個別にエタノールにポリオキシエチレン
硬化ヒマシ油(60.E.O.)、メチルパラベン、香料を溶解
し、前記の水溶液に加えて可溶化し、濾過して化粧水を
得た。Example 29: Lotion lotion component content (% by weight) mugwort extract 1.0 seaweed extract 1.0 mannentake extract 1.0 mint extract 1.0 clara extract 1.0 glycerin 6.0 ethanol 9.0 polyoxyethylene hydrogenated castor oil 0.8 methyl paraben 0.05 citric acid 0.05 sodium citrate 0.07 Fragrance 0.1 Purified water Remainder Total 100.0 Glycerin, citric acid, sodium citrate,
The mugwort extract, seaweed extract, ginseng extract, mint extract and Clara extract obtained in Experimental Example 1 are dissolved. Polyoxyethylene hydrogenated castor oil (60.EO), methyl paraben, and fragrance were individually dissolved in ethanol, added to the above aqueous solution, solubilized, and filtered to obtain a lotion.
【0022】 実施例30:化粧水 成分 配合量(重量%) シャクヤクエキス 1.0 リンゴエキス 1.0 マンネンタケエキス 1.0 クララエキス 1.0 ホウセンカエキス 1.0 グリセリン 6.0 エタノール 9.0 ポリオキシエチレン硬化ヒマシ油 0.8 メチルパラベン 0.05 クエン酸 0.05 クエン酸ナトリウム 0.07 香料 0.1 精製水 残部 合計 100.0 精製水にグリセリン、クエン酸、クエン酸ナトリウム、
実験例1で得たシャクヤクエキスおよびリンゴエキスお
よびマンネンタケエキスおよびクララエキスおよびホウ
センカエキスを溶解する。個別にエタノールにポリオキ
シエチレン硬化ヒマシ油(60.E.O.)、メチルパラベン、
香料を溶解し、前記の水溶液に加えて可溶化し、濾過し
て化粧水を得た。Example 30: Lotion Component Ingredients Amount (wt%) Peony Extract 1.0 Apple Extract 1.0 Mannentake Extract 1.0 Clara Extract 1.0 Datura Extract 1.0 Glycerin 6.0 Ethanol 9.0 Polyoxyethylene Hardened Castor Oil 0.8 Methylparaben 0.05 Citric Acid 0.05 Sodium Citrate 0.07 Fragrance 0.1 Purified water Remainder Total 100.0 Glycerin, citric acid, sodium citrate,
The peony extract, the apple extract, the Ganoderma lucidum extract, the Clara extract and the balsam pear extract obtained in Experimental Example 1 are dissolved. Polyoxyethylene hydrogenated castor oil (60.EO), methyl paraben,
The fragrance was dissolved, added to the aqueous solution to solubilize, and filtered to obtain a lotion.
【0023】 実施例31:クリーム 成分 配合量(重量%) 成分(A) ポリグリセリン脂肪酸エステル 4.0 セタノール 2.0 ステアリン酸 1.0 ミリスチン酸イソプロピル 5.0 オリーブ油 2.0 スクワラン 9.0 自己乳化型モノステアリン酸グリセリル 3.0 パラベン 0.3 成分(B) モモエキス 0.5 アロエエキス 0.5 クララエキス 0.5 ミントエキス 0.5 グリセリン 5.0 トリメチルグリシン 1.0 香料 0.2 精製水 残部 成分(C) 水酸化カリウム水溶液 3.0 (精製水にて100%に調製) 成分(A)を加熱溶解し、80℃にする。別に香料を除
く成分(B)を加熱溶解して80℃に保ち、これに前記
成分(A)を撹拌しながら加えて、充分混合する。さら
に成分(C)を加え、撹拌しながら冷却を行い、香料を
加え、さらに混合してクリームを得た。Example 31: Cream Ingredients Compounding amount (% by weight) Ingredient (A) Polyglycerin fatty acid ester 4.0 Cetanol 2.0 Stearic acid 1.0 Isopropyl myristate 5.0 Olive oil 2.0 Squalane 9.0 Self-emulsifying glyceryl monostearate 3.0 Paraben 0.3 Ingredient (B Peach extract 0.5 Aloe extract 0.5 Clara extract 0.5 Mint extract 0.5 Glycerin 5.0 Trimethylglycine 1.0 Fragrance 0.2 Purified water Remaining component (C) Potassium hydroxide aqueous solution 3.0 (prepared to 100% with purified water) Heat and dissolve component (A), Bring to 80 ° C. Separately, the component (B) excluding the fragrance is dissolved by heating and kept at 80 ° C., and the component (A) is added thereto with stirring and mixed well. Further, the component (C) was added, the mixture was cooled with stirring, a flavor was added, and the mixture was further mixed to obtain a cream.
【0024】 実施例32:クリーム 成分 配合量(重量%) 成分(A) ポリグリセリン脂肪酸エステル 4.0 セタノール 2.0 ステアリン酸 1.0 ミリスチン酸イソプロピル 5.0 オリーブ油 2.0 スクワラン 9.0 自己乳化型モノステアリン酸グリセリル 3.0 パラベン 0.3 成分(B) ハトムギエキス 0.5 シラカバエキス 0.5 オウゴンエキス 0.5 ホウセンカエキス 0.5 ミントエキス 0.5 グリセリン 5.0 トリメチルグリシン 1.0 香料 0.2 精製水 残部 成分(C) 水酸化カリウム水溶液 3.0 (精製水にて100%に調製) 成分(A)を加熱溶解し、80℃にする。別に香料を除
く成分(B)を加熱溶解して80℃に保ち、これに前記
成分(A)を撹拌しながら加えて、充分混合する。さら
に成分(C)を加え、撹拌しながら冷却を行い、香料を
加え、さらに混合してクリームを得た。Example 32: Cream Ingredients Compounding amount (% by weight) Ingredient (A) Polyglycerin fatty acid ester 4.0 Cetanol 2.0 Stearic acid 1.0 Isopropyl myristate 5.0 Olive oil 2.0 Squalane 9.0 Self-emulsifying glyceryl monostearate 3.0 Paraben 0.3 Ingredient (B ) Barley extract 0.5 Birch extract 0.5 Japanese gourd extract 0.5 Balsam pear extract 0.5 Mint extract 0.5 Glycerin 5.0 Trimethylglycine 1.0 Perfume 0.2 Purified water Remaining component (C) Potassium hydroxide aqueous solution 3.0 (prepared to 100% with purified water) Component (A) Heat and melt to 80 ° C. Separately, the component (B) excluding the fragrance is dissolved by heating and kept at 80 ° C., and the component (A) is added thereto with stirring and mixed well. Further, the component (C) was added, the mixture was cooled with stirring, a flavor was added, and the mixture was further mixed to obtain a cream.
【0025】[0025]
【発明の効果】本発明で得られた皮膚外用剤は、優れた
抗炎症、抗かゆみ作用を有し、アトピー性皮膚炎や老人
性掻痒症をはじめとするカユミや炎症を伴なう皮膚症状
を緩和し、その改善に効果を発揮する。さらに、得られ
た皮膚外用剤は、優れた肌荒れ改善に有効であった。The external preparation for skin obtained by the present invention has an excellent anti-inflammatory and anti-itch effect, and skin symptoms accompanied by inflammation and inflammation such as atopic dermatitis and senile pruritus. To alleviate and improve the effect. Furthermore, the obtained external preparation for skin was effective for excellent skin roughness improvement.
───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.7 識別記号 FI テーマコート゛(参考) // A61K 9/06 A61K 9/06 G Fターム(参考) 4C076 AA08 AA12 BB31 CC18 DD37E DD38E DD38F DD43E EE23 EE23A EE54 EE54A EE54E EE58A FF15 FF16 4C083 AA031 AA032 AA111 AA112 AA122 AC022 AC072 AC102 AC122 AC242 AC302 AC352 AC422 AC432 AC482 AC582 AD042 CC03 CC04 CC05 DD22 DD23 DD27 DD31 EE11 EE13 4C088 AA06 AA12 AA18 AB12 AB14 AB16 AB18 AB19 AB25 AB26 AB29 AB32 AB34 AB38 AB40 AB41 AB51 AB52 AB58 AB59 AB60 AB76 AB77 AB81 AB86 AC01 AC02 AC03 AC04 AC05 AC06 AC11 AC13 AC17 BA04 BA05 BA09 BA10 MA07 MA63 NA14 ZA89 ZB11 ZC13 ──────────────────────────────────────────────────続 き Continued on the front page (51) Int.Cl. 7 Identification symbol FI theme coat ゛ (reference) // A61K 9/06 A61K 9/06 GF term (reference) 4C076 AA08 AA12 BB31 CC18 DD37E DD38E DD38F DD43E EE23 EE23A EE54 EE54A EE54E EE58A FF15 FF16 4C083 AA031 AA032 AA111 AA112 AA122 AC022 AC072 AC102 AC122 AC242 AC302 AC352 AC422 AC432 AC482 AC582 AD042 CC03 CC04 CC05 DD22 DD23 DD27 DD31 EE11 EE13 4C088 AA18 AB18A AB18 AB AB51 AB52 AB58 AB59 AB60 AB76 AB77 AB81 AB86 AC01 AC02 AC03 AC04 AC05 AC06 AC11 AC13 AC17 BA04 BA05 BA09 BA10 MA07 MA63 NA14 ZA89 ZB11 ZC13
Claims (1)
少なくとも1種以上の抽出エキスと、ヨモギ、当帰、ワ
レモコウ、カンゾウ、アロエ、ヘチマ、オウゴン、海
藻、カミツレ、クチナシ、クマザサ、クワ、シソ、シラ
カバ、スギナ、セイヨウノコギリソウ、ニンジン、ハマ
メリス、バラ、マロニエ、マンネンタケ、トウキセン
カ、ローズマリー、リンゴ、セイヨウキズク、ハトム
ギ、モモ、アンズ、シャクヤク、ショウキョウ、ホウキ
ギ、ボタンピから選ばれる少なくとも1種以上の抽出エ
キスとを配合することを特徴とする皮膚外用剤。Claims: 1. An extract of at least one selected from Clara, Balsam, and Mint, Artemisia, Toki, Warmoko, Licorice, Aloe, Loofah, Ogon, Seaweed, Chamomile, Gardenia, Kumazasa, Mulberry, Perilla, Birch , Horse chestnut, Achillea millefolium, carrot, hamamelis, rose, marronnier, mannentake, toukisenka, rosemary, apple, pear sword, adlay, peach, apricot, peonies, gingerbread, pear, peanut, buttonpipi and at least one or more extracted extracts An external preparation for skin, characterized by comprising:
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP10230069A JP2000044481A (en) | 1998-07-30 | 1998-07-30 | Preparation for external use for skin |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP10230069A JP2000044481A (en) | 1998-07-30 | 1998-07-30 | Preparation for external use for skin |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2000044481A true JP2000044481A (en) | 2000-02-15 |
Family
ID=16902064
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP10230069A Pending JP2000044481A (en) | 1998-07-30 | 1998-07-30 | Preparation for external use for skin |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2000044481A (en) |
Cited By (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000297044A (en) * | 1999-04-13 | 2000-10-24 | Sunstar Inc | Transdermal patch for external use for skin |
KR20020088004A (en) * | 2001-05-07 | 2002-11-25 | 박종문 | An toilet composition for protecting and combating blemishes and aging of the skin |
JP2003040757A (en) * | 2001-07-25 | 2003-02-13 | Nonogawa Shoji Kk | Skin care preparation |
WO2003015808A1 (en) * | 2001-08-16 | 2003-02-27 | Hnat Thomas M | Method and composition for treatment of wounds and burns |
KR100384661B1 (en) * | 2000-12-18 | 2003-05-22 | 강삼식 | Anti-inflammatory prenylated flavonoid derivatives and extract of Sophora flavescens therewith |
JP2003155246A (en) * | 2001-11-20 | 2003-05-27 | Fancl Corp | Stimulant relief composition |
WO2003086432A1 (en) * | 2002-04-15 | 2003-10-23 | Tetsuo Santo | Therapeutic lotion for dermatitis |
WO2003086434A1 (en) * | 2002-04-15 | 2003-10-23 | Tetsuo Santo | Drinking tea for treating dermatitis |
WO2003086433A1 (en) * | 2002-04-15 | 2003-10-23 | Tetsuo Santo | Therapeutic cream for dermatitis |
WO2004009105A1 (en) * | 2002-07-18 | 2004-01-29 | Antonio Carlos Pereira Coelho | Phytotherapic composition based on vegetable extracts, process for obtainment of said composition and use of vegetable extracts for preparation of a phytotherapic composition |
EP1304115A4 (en) * | 2000-07-26 | 2004-07-21 | Hououdou Co Ltd | Antipruritic compositions and compositions promoting wound healing |
WO2002045733A3 (en) * | 2000-12-08 | 2004-10-14 | Kyowa Hakko Kogyo Kk | Oral preprations having itching-relievign or antipruritic activity |
JP2006176436A (en) * | 2004-12-22 | 2006-07-06 | Kao Corp | SCF expression inhibitor |
ES2259274A1 (en) * | 2006-05-24 | 2006-09-16 | Francisca Garcia Vizcaino | Healing cream is for damaged skin with problems of psoriasis, dermatitis, itching, eczema |
EP1707213A1 (en) * | 2005-03-17 | 2006-10-04 | Elisabeth Kern | Herbal composition for the treatment of cutaneous Erythema |
JP2007505151A (en) * | 2003-05-25 | 2007-03-08 | 杭州浙大力夫生物科技有限公司 | Application of bamboo leaf flavone in preventive and therapeutic drugs for prostate diseases and health foods |
WO2008044894A1 (en) * | 2006-10-12 | 2008-04-17 | Unigen, Inc. | Composition for treating atopic dermatitis comprising extracts of bamboo and scutellaria |
JP2009084222A (en) * | 2007-09-28 | 2009-04-23 | Naris Cosmetics Co Ltd | Nerve growth factor (NGF) production inhibitor and itching inhibitor external preparation |
EP1737475A4 (en) * | 2004-03-19 | 2009-08-05 | Xiu-Min Li | Herbal therapy for the treatment of asthma |
US7645462B2 (en) * | 2002-08-27 | 2010-01-12 | 3T Herbtech, Inc. | Acupoint patch |
DE102008002999A1 (en) * | 2008-08-12 | 2010-02-25 | Manfred Engels | Composition, useful as anticancer or immunostimulants, cosmetics, preferably hair growth- and/or nail care products, dietary supplement and all-purpose cleaners and to treat e.g. gastric ulcers and cold, comprises ginger and chamomile |
JP2011219402A (en) * | 2010-04-08 | 2011-11-04 | Pola Chemical Industries Inc | Pomc production inhibitor |
CN103083441A (en) * | 2012-11-09 | 2013-05-08 | 苗遐 | Traditional Chinese medicine scouring bath agent for treating hemorroide gall |
CN103316114A (en) * | 2013-07-09 | 2013-09-25 | 陈静静 | Traditional Chinese medicine for treating AS (Ankylosing Spondylitis) |
US8568799B2 (en) | 2002-03-22 | 2013-10-29 | Unigen, Inc. | Isolation of a dual COX-2 and 5-lipoxygenase inhibitor from acacia |
US8652535B2 (en) | 2002-04-30 | 2014-02-18 | Unigen, Inc. | Formulation of a mixture of free-B-ring flavonoids and flavans for use in the prevention and treatment of cognitive decline and age-related memory impairments |
US8790724B2 (en) | 2003-04-04 | 2014-07-29 | Unigen, Inc. | Formulation of dual cycloxygenase (COX) and lipoxygenase (LOX) inhibitors for mammal skin care |
US9061039B2 (en) | 2002-03-01 | 2015-06-23 | Unigen, Inc. | Identification of Free-B-Ring flavonoids as potent COX-2 inhibitors |
US9370544B2 (en) | 2002-04-30 | 2016-06-21 | Unigen, Inc. | Formulation of a mixture of free-B-ring flavonoids and flavans as a therapeutic agent |
CN106821859A (en) * | 2017-03-16 | 2017-06-13 | 上海芝映生物科技有限公司 | A kind of preparation method of the composite plant extract liquid with antiallergic itching-relieving action |
CN109125207A (en) * | 2018-09-21 | 2019-01-04 | 广州栋方生物科技股份有限公司 | A kind of plant compound of antibacterial anti-acne and its preparation method and application |
JP2020007258A (en) * | 2018-07-06 | 2020-01-16 | 花王株式会社 | Antimicrobial peptide expression promoter |
CN113208976A (en) * | 2020-09-07 | 2021-08-06 | 北京工商大学 | Skin-firming and nourishing ganoderma lucidum composite fermentation product and preparation method and application thereof |
JP7023026B1 (en) | 2021-05-18 | 2022-02-21 | 株式会社アイビー化粧品 | JAK inhibitor |
Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH01102027A (en) * | 1987-10-15 | 1989-04-19 | Nitto Denko Corp | Production of antiallergic drug |
JPH04356423A (en) * | 1991-05-31 | 1992-12-10 | Masao Saito | Medicated cream and its production |
JPH07277939A (en) * | 1994-04-05 | 1995-10-24 | Dowa Mining Co Ltd | Skin external preparation |
JPH07330624A (en) * | 1994-06-10 | 1995-12-19 | Sunstar Inc | Antiinflammatory and antipruritic agent |
JPH0873314A (en) * | 1994-09-05 | 1996-03-19 | Ichimaru Pharcos Co Ltd | External preparation for skin and bathing agent |
JPH0987189A (en) * | 1995-09-19 | 1997-03-31 | Ichimaru Pharcos Co Ltd | Antiallergic agent containing isodon japonicus hara, paeonia suffruticosa andrews, perilla frutescens britton var. acuta kudo, and/or arunica montana linne |
JPH09157176A (en) * | 1995-12-05 | 1997-06-17 | Ichimaru Pharcos Co Ltd | Antiallergic agent containing extract of hypericum erectum thunb. and tilia miqueliana maxim. |
JPH09194385A (en) * | 1996-01-10 | 1997-07-29 | Ichimaru Pharcos Co Ltd | Antiallergic agent and preparation for external use for skin or bathing agent blended with the same agent |
JPH09227390A (en) * | 1996-02-19 | 1997-09-02 | Pola Chem Ind Inc | Composition for improving skin condition |
JPH09255583A (en) * | 1996-03-25 | 1997-09-30 | Yamamoto Koryo Kk | Antipruritic agent |
JPH09291011A (en) * | 1996-04-24 | 1997-11-11 | Kose Corp | Composition suitable for eternal use |
JPH1017461A (en) * | 1996-06-28 | 1998-01-20 | Shiseido Co Ltd | Preparation for external use for improving skin roughness |
JPH10139679A (en) * | 1996-11-05 | 1998-05-26 | Noevir Co Ltd | Isolation inhibitor of chemical mediator, and cosmetic, medicine and food including the same |
-
1998
- 1998-07-30 JP JP10230069A patent/JP2000044481A/en active Pending
Patent Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH01102027A (en) * | 1987-10-15 | 1989-04-19 | Nitto Denko Corp | Production of antiallergic drug |
JPH04356423A (en) * | 1991-05-31 | 1992-12-10 | Masao Saito | Medicated cream and its production |
JPH07277939A (en) * | 1994-04-05 | 1995-10-24 | Dowa Mining Co Ltd | Skin external preparation |
JPH07330624A (en) * | 1994-06-10 | 1995-12-19 | Sunstar Inc | Antiinflammatory and antipruritic agent |
JPH0873314A (en) * | 1994-09-05 | 1996-03-19 | Ichimaru Pharcos Co Ltd | External preparation for skin and bathing agent |
JPH0987189A (en) * | 1995-09-19 | 1997-03-31 | Ichimaru Pharcos Co Ltd | Antiallergic agent containing isodon japonicus hara, paeonia suffruticosa andrews, perilla frutescens britton var. acuta kudo, and/or arunica montana linne |
JPH09157176A (en) * | 1995-12-05 | 1997-06-17 | Ichimaru Pharcos Co Ltd | Antiallergic agent containing extract of hypericum erectum thunb. and tilia miqueliana maxim. |
JPH09194385A (en) * | 1996-01-10 | 1997-07-29 | Ichimaru Pharcos Co Ltd | Antiallergic agent and preparation for external use for skin or bathing agent blended with the same agent |
JPH09227390A (en) * | 1996-02-19 | 1997-09-02 | Pola Chem Ind Inc | Composition for improving skin condition |
JPH09255583A (en) * | 1996-03-25 | 1997-09-30 | Yamamoto Koryo Kk | Antipruritic agent |
JPH09291011A (en) * | 1996-04-24 | 1997-11-11 | Kose Corp | Composition suitable for eternal use |
JPH1017461A (en) * | 1996-06-28 | 1998-01-20 | Shiseido Co Ltd | Preparation for external use for improving skin roughness |
JPH10139679A (en) * | 1996-11-05 | 1998-05-26 | Noevir Co Ltd | Isolation inhibitor of chemical mediator, and cosmetic, medicine and food including the same |
Cited By (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000297044A (en) * | 1999-04-13 | 2000-10-24 | Sunstar Inc | Transdermal patch for external use for skin |
EP1304115A4 (en) * | 2000-07-26 | 2004-07-21 | Hououdou Co Ltd | Antipruritic compositions and compositions promoting wound healing |
WO2002045733A3 (en) * | 2000-12-08 | 2004-10-14 | Kyowa Hakko Kogyo Kk | Oral preprations having itching-relievign or antipruritic activity |
KR100384661B1 (en) * | 2000-12-18 | 2003-05-22 | 강삼식 | Anti-inflammatory prenylated flavonoid derivatives and extract of Sophora flavescens therewith |
KR20020088004A (en) * | 2001-05-07 | 2002-11-25 | 박종문 | An toilet composition for protecting and combating blemishes and aging of the skin |
JP2003040757A (en) * | 2001-07-25 | 2003-02-13 | Nonogawa Shoji Kk | Skin care preparation |
WO2003015808A1 (en) * | 2001-08-16 | 2003-02-27 | Hnat Thomas M | Method and composition for treatment of wounds and burns |
US7597911B2 (en) * | 2001-08-16 | 2009-10-06 | Curapharm, Inc. | Method and composition for treatment of wounds and burns |
JP2003155246A (en) * | 2001-11-20 | 2003-05-27 | Fancl Corp | Stimulant relief composition |
US9061039B2 (en) | 2002-03-01 | 2015-06-23 | Unigen, Inc. | Identification of Free-B-Ring flavonoids as potent COX-2 inhibitors |
US9168242B2 (en) | 2002-03-22 | 2015-10-27 | Unigen, Inc. | Isolation of a dual COX-2 and 5-lipdxygenase inhibitor from Acacia |
US8568799B2 (en) | 2002-03-22 | 2013-10-29 | Unigen, Inc. | Isolation of a dual COX-2 and 5-lipoxygenase inhibitor from acacia |
JPWO2003086433A1 (en) * | 2002-04-15 | 2005-08-18 | 哲夫 山東 | Dermatitis treatment cream |
WO2003086432A1 (en) * | 2002-04-15 | 2003-10-23 | Tetsuo Santo | Therapeutic lotion for dermatitis |
JPWO2003086432A1 (en) * | 2002-04-15 | 2005-08-18 | 哲夫 山東 | Dermatitis lotion |
EP1495762A4 (en) * | 2002-04-15 | 2006-04-12 | Tetsuo Santo | Therapeutic lotion for dermatitis |
US7615239B2 (en) | 2002-04-15 | 2009-11-10 | Tetsuo Santo | Tea for treating dermatitis comprising herbal extracts |
WO2003086433A1 (en) * | 2002-04-15 | 2003-10-23 | Tetsuo Santo | Therapeutic cream for dermatitis |
US7572469B2 (en) | 2002-04-15 | 2009-08-11 | Tetsuo Santo | Therapeutic lotion for dermatitis |
JPWO2003086434A1 (en) * | 2002-04-15 | 2005-08-18 | 哲夫 山東 | Drinking tea for dermatitis treatment |
WO2003086434A1 (en) * | 2002-04-15 | 2003-10-23 | Tetsuo Santo | Drinking tea for treating dermatitis |
US9655940B2 (en) | 2002-04-30 | 2017-05-23 | Unigen, Inc. | Formulation of a mixture of free-B-ring flavonoids and flavans as a therapeutic agent |
US9370544B2 (en) | 2002-04-30 | 2016-06-21 | Unigen, Inc. | Formulation of a mixture of free-B-ring flavonoids and flavans as a therapeutic agent |
US9849152B2 (en) | 2002-04-30 | 2017-12-26 | Unigen, Inc. | Formulation of a mixture of Free-B-ring flavonoids and flavans as a therapeutic agent |
US8652535B2 (en) | 2002-04-30 | 2014-02-18 | Unigen, Inc. | Formulation of a mixture of free-B-ring flavonoids and flavans for use in the prevention and treatment of cognitive decline and age-related memory impairments |
WO2004009105A1 (en) * | 2002-07-18 | 2004-01-29 | Antonio Carlos Pereira Coelho | Phytotherapic composition based on vegetable extracts, process for obtainment of said composition and use of vegetable extracts for preparation of a phytotherapic composition |
US7645462B2 (en) * | 2002-08-27 | 2010-01-12 | 3T Herbtech, Inc. | Acupoint patch |
US9622964B2 (en) | 2003-04-04 | 2017-04-18 | Unigen, Inc. | Formulation of dual cycloxygenase (COX) and lipoxygenase (LOX) inhibitors for mammal skin care |
US8790724B2 (en) | 2003-04-04 | 2014-07-29 | Unigen, Inc. | Formulation of dual cycloxygenase (COX) and lipoxygenase (LOX) inhibitors for mammal skin care |
JP2007505151A (en) * | 2003-05-25 | 2007-03-08 | 杭州浙大力夫生物科技有限公司 | Application of bamboo leaf flavone in preventive and therapeutic drugs for prostate diseases and health foods |
EP1737475A4 (en) * | 2004-03-19 | 2009-08-05 | Xiu-Min Li | Herbal therapy for the treatment of asthma |
US7854935B2 (en) | 2004-03-19 | 2010-12-21 | Herbal Spring, Llc | Herbal therapy for the treatment of asthma |
EP2532353A1 (en) * | 2004-03-19 | 2012-12-12 | Herbs Spring, LLC | Herbal therapy for the treatment of asthma |
JP2006176436A (en) * | 2004-12-22 | 2006-07-06 | Kao Corp | SCF expression inhibitor |
EP1707213A1 (en) * | 2005-03-17 | 2006-10-04 | Elisabeth Kern | Herbal composition for the treatment of cutaneous Erythema |
ES2259274A1 (en) * | 2006-05-24 | 2006-09-16 | Francisca Garcia Vizcaino | Healing cream is for damaged skin with problems of psoriasis, dermatitis, itching, eczema |
ES2259274B2 (en) * | 2006-05-24 | 2007-03-16 | Francisca Garcia Vizcaino | REPAIR CREAM FOR DAMAGED SKIN. |
WO2008044894A1 (en) * | 2006-10-12 | 2008-04-17 | Unigen, Inc. | Composition for treating atopic dermatitis comprising extracts of bamboo and scutellaria |
CN101616681B (en) * | 2006-10-12 | 2013-07-10 | 株式会社优力竟 | Composition for treating atopic dermatitis comprising extracts of bamboo and scutellaria |
US8247007B2 (en) | 2006-10-12 | 2012-08-21 | Unigen, Inc. | Composition for treating atopic dermatitis comprising extracts of bamboo and Scutellaria |
US8771761B2 (en) | 2006-10-12 | 2014-07-08 | Unigen, Inc. | Composition for treating atopic dermatitis comprising extracts of bamboo and scutellaria |
JP2010505944A (en) * | 2006-10-12 | 2010-02-25 | ユニジェン インク. | Composition for the treatment of atopic dermatitis containing bamboo extract and Koganebana extract |
AU2007307427B2 (en) * | 2006-10-12 | 2013-05-09 | Unigen, Inc. | Composition for treating atopic dermatitis comprising extracts of Bamboo and Scutellaria |
US9623068B2 (en) | 2006-10-12 | 2017-04-18 | Unigen, Inc. | Composition for treating atopic dermatitis comprising extracts of bamboo and scutellaria |
JP2009084222A (en) * | 2007-09-28 | 2009-04-23 | Naris Cosmetics Co Ltd | Nerve growth factor (NGF) production inhibitor and itching inhibitor external preparation |
DE102008002999A1 (en) * | 2008-08-12 | 2010-02-25 | Manfred Engels | Composition, useful as anticancer or immunostimulants, cosmetics, preferably hair growth- and/or nail care products, dietary supplement and all-purpose cleaners and to treat e.g. gastric ulcers and cold, comprises ginger and chamomile |
JP2011219402A (en) * | 2010-04-08 | 2011-11-04 | Pola Chemical Industries Inc | Pomc production inhibitor |
CN103083441A (en) * | 2012-11-09 | 2013-05-08 | 苗遐 | Traditional Chinese medicine scouring bath agent for treating hemorroide gall |
CN103316114A (en) * | 2013-07-09 | 2013-09-25 | 陈静静 | Traditional Chinese medicine for treating AS (Ankylosing Spondylitis) |
CN106821859A (en) * | 2017-03-16 | 2017-06-13 | 上海芝映生物科技有限公司 | A kind of preparation method of the composite plant extract liquid with antiallergic itching-relieving action |
JP2020007258A (en) * | 2018-07-06 | 2020-01-16 | 花王株式会社 | Antimicrobial peptide expression promoter |
JP7138496B2 (en) | 2018-07-06 | 2022-09-16 | 花王株式会社 | Antimicrobial peptide expression promoter |
CN109125207A (en) * | 2018-09-21 | 2019-01-04 | 广州栋方生物科技股份有限公司 | A kind of plant compound of antibacterial anti-acne and its preparation method and application |
CN113208976A (en) * | 2020-09-07 | 2021-08-06 | 北京工商大学 | Skin-firming and nourishing ganoderma lucidum composite fermentation product and preparation method and application thereof |
JP7023026B1 (en) | 2021-05-18 | 2022-02-21 | 株式会社アイビー化粧品 | JAK inhibitor |
JP2022177590A (en) * | 2021-05-18 | 2022-12-01 | 株式会社アイビー化粧品 | JAK inhibitor |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2000044481A (en) | Preparation for external use for skin | |
EP2278986B1 (en) | A product for topical administration | |
US6395311B2 (en) | Multicomponent biological vehicle | |
JPH10130162A (en) | Hyaluronic acid decomposition inhibitor, agent for treatment of hyaluronic acid abnormal decomposition disease and cosmetic | |
CN113521164B (en) | Tibetan medicine composition with antibacterial effect and preparation method and application thereof | |
KR20140071738A (en) | Cosmetic composition for alleviating dermatitis and skin irritation | |
CN111281966B (en) | Composition containing earthworm protein, preparation method and application thereof | |
CN114432225A (en) | Sunscreen skin care product and preparation method thereof | |
CN112022767B (en) | Anti-inflammatory antibacterial immunity-enhancing acne-removing composition and application thereof | |
WO2006043771A1 (en) | Composition comprising extract of anemarrhena asphodeloides and aralia elata, and use thereof | |
KR20060083567A (en) | Herbal cosmetic composition for atopic skin containing specific herbal extract mixture | |
ES2394316T3 (en) | Pharmaceutical compositions of Carapa Guianensis. | |
CN111789799A (en) | Plant composition with red-removing, anti-inflammatory and relieving effects and application thereof | |
CN106620633A (en) | Skin repairing cream for tumor patients and preparation method of skin repairing cream | |
KR20090126992A (en) | Camellia gourd (camellia seed shell powder) and its use | |
CN108853249A (en) | It is a kind of to treat dermopathic plastics | |
KR20110121295A (en) | External skin composition for relieving menstrual pain | |
KR20060074038A (en) | Composition having a prophylactic effect of atopic dermatitis | |
KR100644086B1 (en) | Method of manufacturing herbal baths without skin irritation | |
JP5030366B2 (en) | Composition for treatment of allergic diseases | |
KR100820343B1 (en) | Compositions for treating inflammatory dermatological disease | |
CN104940524B (en) | It is a kind of to be used to treat drug of leucoderma and preparation method thereof | |
KR20030092519A (en) | Composition for improving or preventing of allergic dermatological diseases | |
Oladele et al. | Evaluation of anti-inflammatory and membrane stabilizing effects of aqueous root extract of Boerhavia diffusa Linn. in rats | |
Ray | Scope of Aloe vera as Medicinal Plant and skin care |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20060228 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060307 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060427 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20070807 |